Evidence map›Paper›PMID 38635633›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Dual function of LapB (YciM) in regulating

Sheng Shu, Yuko Tsutsui, Rajkanwar Nathawat, Wei Mi

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sheng ShuDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.ORCID 0000-0002-1604-4732
Yuko TsutsuiDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.ORCID 0000-0002-3286-3295
Rajkanwar NathawatDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.ORCID 0000-0003-1089-5461
Wei MiDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.ORCID 0000-0002-2845-4608
Yale University · USYale Cancer Center · US

Funding

Understanding how membrane composition directs membrane protein structure and functionRM1GM149406 · NIGMS · YALE UNIVERSITY · PI Joel Adam Butterwick, KATHRYN M FERGUSON · 2023 to 2026
$8.4M
Understanding Signaling by Non-Canonical Receptor Tyrosine KinasesR35GM122485 · NIGMS · YALE UNIVERSITY · PI Mark A Lemmon · 2017 to 2026
$7.9M
High-throughput electron cryo-microscopeS10OD023603 · OD · YALE UNIVERSITY · PI SIGWORTH, FREDERICK J · 2018 to 2018
$1.9M
Molecular Mechanisms of the Type I Secretion System from Bacterial PathogensR01GM137068 · NIGMS · YALE UNIVERSITY · PI MI, WEI · 2021 to 2025
$1.9M
NIGMS NIH HHS R01 GM137068NIGMS NIH HHS R35 GM122485NIGMS NIH HHS RM1 GM149406NIH HHS S10 OD023603
6 · The paper itself

Abstract

Levels of lipopolysaccharide (LPS), an essential glycolipid on the surface of most gram-negative bacteria, are tightly controlled-making LPS synthesis a promising target for developing new antibiotics.

Indexed as

Escherichia coliEscherichia coli ProteinsAmidohydrolasesLipopolysaccharidesMembrane ProteinsMutationRubredoxinsAmidohydrolasesEscherichia coli ProteinsLipopolysaccharidesMembrane ProteinsRubredoxinsYciM protein, E coliLapB (YciM)LPS synthesisLpxCRegulation

Identifiers

PMID38635633
PMCPMC11046580
OpenAlexW4394933385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.